Maximilien Murone interview

Avrion CEO Maximilien Murone discusses Avrion and his management philosophy as part of the Sejelas Founders-CEO interview series.
Excerpt -


Maximilien Murone: Avrion comes from the Greek word – “of tomorrow”, as our company aspires to deliver therapies of tomorrow.

While gene therapy solutions represented a new therapeutic modality patients hoped for since several decades, today gene therapy has become a reality with several disruptive products on the market, and many more in clinical development. Some forms of blindness can be corrected today by gene therapy, as well as other life-threatening genetic disorders.

There is a big medical need for therapies addressing neurodegenerative disorders. The ageing population is growing and with this, also the number of cases of patients affected by neurodegenerative diseases, like Parkinson’s disease, etc.

We decided to position ourselves first in a rare neurodegenerative disorder called Amyotrophic Lateral Sclerosis (ALS) due to the absence of cure for this deadly disease, and the possibility to reach rapidly proof of clinical efficacy in ALS patients.

In ALS, the death of motor neurons leads to progressive paralysis of patients, who end up literally “prisoners of their own body”, while perfectly conscious.

There are today 2 drugs on the market which bring only marginal benefits to the ALS patients, and no cure. We hope that with our precision gene therapy approach, we will be able to bring transformational solutions to ALS patients.

Read the full Sejelas Founders-CEO interview with the Avrion CEO Maximilien Murone here.